According to DFE Pharma, the company has significantly increased production capacities of its excipients, including all of its inhalation grade lactose products.
The company said that it achieved the improved supply through investments at facilities in the Netherlands, Germany, and India. Inhalation grade lactose is produced at the plant in Veghel, the Netherlands.
DFE Pharma CEO Bas van Driel commented, ‘We are excited that our team has further shortened our lead times and improved our reliability to meet and exceed our customers’ expectations. All products are as you could expect from DFE Pharma of highest quality, within the agreed specs and consistency.”
